Investigator-initiated trials (IITs) are established and managed by non-pharmaceutical researchers, such as clinicians and researchers working in a health institution.

The 2023 AACR Congress set the scene with the revelation of the latest clinical outcomes of HS-10365, a highly potent and selective RET TKI, offering significant insights into its potential therapeutic benefits.

Abeona Therapeutics Inc. confirms FDA priority review for their therapy, pz-cel (prademagene zamikeracel), Biologics License Application.

FLT3 inhibitors are drugs that competitively inhibit the ATP binding site in the FLT3 receptor, leading to cell cycle arrest and differentiation.

In the Phase III trial for the initial treatment of recurrent/metastatic cervical cancer in all types of patients, Cadonilimab (PD-1/CTLA-4 Bispecific Antibody) has achieved the primary goal of halting disease progression.

New clinical results for Tebotelimab, a PD-1/LAG-3 dual antibody, shown at 2023 AACR, reveal promise for untreated advanced mucosal melanoma.

Gracell Biotechnologies reveals FDA approval for a Phase 1/2 Clinical Trial IND application concerning FasTCAR-T GC012F, aimed at treating stubborn Systemic Lupus Erythematosus.

HDAC6 inhibitors are effective chemotherapy agents that modulate protein acetylation, boost p21 gene expression, and hinder tumor growth through cell differentiation or apoptosis.

TC BioPharm PLC, a clinical-stage biotech company focused on allogeneic gamma-delta T cell cancer therapies, has announced FDA approval for its investigational new drug application to enter a Phase 1B trial for recurrent and refractory Acute Myeloid Leukemia.

Interim results from a human trial on PLB-1004 presented at the 2023 AACR Congress highlight its clinical promise.

The first participant has been dosed in OncoNano Medicine's Phase 1 trial of ONM-501 for individuals with advanced solid cancers and lymphomas.

KRAS G12C is a specific mutation of the KRAS gene that plays a crucial role in the development and progression of certain cancers.